|
|
Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)
Over 5.7 million people in the US and 20 million people worldwide suffer from heart failure. About half of these patients suffer from Heart Failure with Preserved Ejection Fraction (HFpEF) and are without effective treatment. CorAssist is developing the first device focused on treating HFpEF patients.
CorAssist is committed to developing innovative therapeutic products for treating HFpEF. The company's product, the CORolla® is the first device to directly improve cardiac diastolic function, and can be implanted in Trans Apical or Percutaneous approach.
Another group of patients who can benefit from CorAssist’s technology, are patients with diastolic dysfunction secondary to aortic stenosis undergoing AVR. In this group, diastolic function is not improving or just slightly improving post-surgery and the prognosis compared to patients undergoing AVR without diastolic dysfunction is worse. The CORolla® may improve diastolic function in these patients as well.
|
 |
CORolla®
The CORolla® is an elastic self-expanding internal spring-like device implanted inside the Left Ventricle (LV) through a minimally invasive (left thoracotomy) or percutaneous (trans catheter) procedure. The device applies direct expansion forces on the LV wall and the septum.
Read more..
ImCardia®
The company's first product, the ImCardia®, demonstrated proof of concept of direct cardiac diastolic function improvement.
Read more..
|
